A compound being "in clinical trials" sounds like a status update, but it can mean anything from a 20-person safety study to a multi-year, multi-thousand-person trial nearing approval. Here’s how to tell the difference.
Want something built around your specific situation, not general reading? PeptideReport.ai turns a short guided intake into a free, personalized educational report you can actually bring to your doctor — and registering gets you The Peptide Bridge audiobook free, a $29.99 value, delivered to your inbox right away.
Get my free report + free book →Phase 1 typically involves a small group (often a few dozen people) and focuses on safety and dosing range, not effectiveness. Phase 2 expands to a larger group and starts looking at whether the compound actually does what it's supposed to, alongside continued safety monitoring. Phase 3 is the large-scale trial — often hundreds to thousands of participants across multiple sites — that's designed to be definitive enough to support an approval decision. A compound can spend years in any one of these phases, or stall out and never move to the next one at all.
Marketing copy often treats "currently in clinical trials" as evidence of imminent legitimacy. In reality, a huge number of compounds enter Phase 1 and never make it further — failed trials are the norm, not the exception, across drug development generally. Being in trials is a necessary step, not a guarantee, and it says very little on its own about how likely a compound is to eventually reach approval.
ClinicalTrials.gov is the US government's public registry of clinical trials and is free to search directly. Searching a compound's name there shows you real information: what phase a trial is in, how many participants, what it's actually testing for, and whether the trial is recruiting, active, completed, or terminated. This is a far more reliable source than a vendor's characterization of "clinical trial data" in marketing copy — our research literacy guide walks through how to read what you find there.
Retatrutide (see the extended compounds list) is a useful case study: it has genuine, well-documented Phase 3 trial activity, which is a meaningfully more advanced and reliable status than a compound with only a single small Phase 1 study to its name — even though both could technically be described as "in clinical trials."
For how to read a specific paper or trial result once you find it, see the research literacy guide. For the regulatory categories that sit downstream of trial results, see are research peptides legal.
Reading about this by name is a starting point, not a plan. PeptideReport.ai turns general reading like this into a free, personalized report you can bring to a licensed physician — the person actually qualified to weigh these considerations against your health history.
Get your free report at PeptideReport.ai →
Free bonus: register today and The Peptide Bridge audiobook — a physician-authored, plain-English guide to peptide therapy, a $29.99 value — is yours free, delivered to your inbox right away.